drugset / Trial / NCT05684744
Roflumilast Versus Methotrexate in Psoriasis
RandomizedParallel-groupDouble-blindTreatment
Summary
Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor, which is approved in its oral form for chronic obstructive pulmonary disease, and in its topical form in the treatment of plaque psoriasis. Methotrexate is one of the conventional systemic treatments of psoriasis, so the aim of this study is to compare the efficacy and safety of roflumilast and methotrexate in the treatment of psoriasis
Timeline
- Start
- 2023-01-09
- Primary completion
- 2023-05-09
- Completion
- 2023-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Methotrexate | Small molecule | 0.2 mg/kg | Oral |
| Comparator | Methotrexate | Small molecule | 0.4 mg/kg | Oral |
| Subject | Roflumilast | Small molecule | 500 ug | Oral |